Successful Out-Licensing of APHEXDA
BioLineRx entered into an exclusive out-licensing agreement with Ayrmid Pharma Limited for APHEXDA, which is FDA-approved for stem cell mobilization. This agreement includes substantial commercial milestones and royalties.
Significant Reduction in Operating Expenses
BioLineRx reduced its operating cash burn by over 70%, from $40 million annually to less than $12 million, following the restructuring and out-licensing agreement with Ayrmid.
Financial Stability and Strong Cash Position
The company ended the first quarter of 2025 with $26.4 million in cash, a strong financial footing, and a cash runway expected to fund operations through the second half of 2026.
Encouraging APHEXDA Sales
APHEXDA generated $1.4 million in sales in Q1 2025, resulting in $0.3 million in royalty revenues for BioLineRx after returning to growth under Ayrmid's stewardship.
Promising Developments in Pancreatic Cancer Trial
Motixafortide showed a 64% response rate in a pilot study for pancreatic cancer, with new data to be presented at ASCO 2025. This compares favorably to historical response rates.